Adaptive Biotechnologies appoints Kyle Piskel as CFO effective April 8, 2024

Adaptive Biotechnologies Corp

Kyle Piskel promoted from Principal Accounting Officer to CFO; reports to CEO Chad Robins.
Base salary set at $380,000 per year; target bonus of 40% of eligible earnings.
Receives RSU grant of 31,260 shares (4-year vesting) and PSU grant of 75,000 shares (3-year performance period).
Also entitled to annual equity refresh of 43,740 RSUs, bringing 2024 total equity grants to 150,000 shares.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Kyle Piskel

Chief Financial Officer

ADPT · Adaptive Biotechnologies Corp

Effective: 2024-04-08
Filed: April 9, 2024, 7:59 PM ET

As previously announced, Adaptive Biotechnologies Corporation (the “ Company ”) appointed Kyle Piskel, the Company’s Principal Accounting Officer, to serve as its Chief Financial Officer effective April 8, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kyle Piskel was appointed as Chief Financial Officer at Adaptive Biotechnologies Corp.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

As previously announced, Adaptive Biotechnologies Corporation (the “ Company ”) appointed Kyle Piskel, the Company’s Principal Accounting Officer, to serve as its Chief Financial Officer effective April 8, 2024.

View on SEC.gov

Adaptive Biotechnologies Corp filing history →

Source: SEC EDGAR

accession 0001193125-24-090983

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.